Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PPM1B | O75688 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5186955 | 0.82 | ALDH1A1 (0.38) | ALDH1A1TDP1PPM1BPTPN1PPP1CC | |
| SCHEMBL9253272 | 0.80 | PPM1B (0.34) | ALDH1A1PPM1BPTPN1PPP1CCMAPT | |
| SCHEMBL10404054 | 0.80 | — | — | |
| SCHEMBL4304520 | 0.80 | TP53 (0.37) | — | |
| SCHEMBL9808616 | 0.78 | — | — | |
| SCHEMBL13072517 | 0.77 | — | — | |
| SCHEMBL9253268 | 0.77 | — | — | |
| SCHEMBL10333430 | 0.75 | NPC1 (0.31) | MAPT | |
| SCHEMBL9564946 | 0.74 | LMNA (0.52) | ALDH1A1KMT2APOLB | |
| SCHEMBL7921737 | 0.74 | PPM1B (0.40) | ALDH1A1PPM1BPTPN1PPP1CCCYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0514515-A1 | ANTHRACYCLINE-CONJUGATES. | ERBA CARLO SPA (IT) | 1992-11-25 | — | — | EP | claimed |
| WO-1992010212-A1 | ANTHRACYCLINE-CONJUGATES | FARMITALIA CARLO ERBA SRL (IT) | 1992-06-25 | — | — | WO | claimed |
| US-12054484-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20220153733-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220153733-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2022-05-19 | — | — | US | disclosed |
| EP-3297438-B1 | CCR2 MODULATORS | CHEMOCENTRYX INC (US) | 2021-10-20 | — | — | EP | disclosed |
| CN-108135168-B | CCR2 modulators | 凯莫森特里克斯股份有限公司 | 2021-07-20 | — | — | CN | disclosed |
| US-20200121688-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2020-04-23 | — | — | US | disclosed |
| US-20200121688-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2020-04-23 | — | — | US | disclosed |
| US-10464934-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180086756-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2018-03-29 | — | — | US | disclosed |
| WO-2016187393-A1 | CCR2 MODULATORS | CHEMOCENTRYX, INC. (US) | 2016-11-24 | — | — | WO | disclosed |
| WO-2016187393-A1 | CCR2 MODULATORS | CHEMOCENTRYX, INC. (US) | 2016-11-24 | — | — | WO | disclosed |
| US-20160340356-A1 | CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2016-11-24 | — | — | US | disclosed |
| US-20120022045-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | VENKATRAMAN SHANKAR (US) | 2012-01-26 | — | — | US | disclosed |
| US-5776458-A | ANTITUMOR AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 1998-07-07 | — | — | US | disclosed |
| EP-0514515-B1 | ANTHRACYCLINE-CONJUGATES | PHARMACIA & UPJOHN SPA (IT) | 1997-04-16 | — | — | EP | disclosed |
| EP-0514515-A1 | ANTHRACYCLINE-CONJUGATES. | ERBA CARLO SPA (IT) | 1992-11-25 | — | — | EP | disclosed |
| WO-1992010212-A1 | ANTHRACYCLINE-CONJUGATES | FARMITALIA CARLO ERBA SRL (IT) | 1992-06-25 | — | — | WO | disclosed |
| US-4677190-A | Synthesis and ring-opening polymerization of bicyclic lactones containing a tetrahydropyran ring | UNIVERSITY PATENTS, INC. (US) | 1987-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464934-B2 | Substituted tetrahydropyrans as CCR2 modulators | CCR2, CCR1, CCR5 | ALDH1A1 1316/4885USP2 4725/4885ALOX15 1844/4885 |
| US-20120022045-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | CCND3, CDK3, CDK2 | ALDH1A1 2994/4885USP2 3207/4885ALOX15 4800/4885 |
| US-20180086756-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | ALDH1A1 1316/4885USP2 4725/4885ALOX15 1844/4885 |
| US-12054484-B2 | Substituted tetrahydropyrans as CCR2 modulators | CCR2, CCR1, CCR5 | ALDH1A1 538/4885USP2 4484/4885ALOX15 1717/4885 |
| US-20200121688-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | ALDH1A1 1316/4885USP2 4725/4885ALOX15 1844/4885 |
| US-20220153733-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | ALDH1A1 520/4885USP2 4505/4885ALOX15 1670/4885 |
| US-20160340356-A1 | CCR2 MODULATORS | CCR2, CCR1, CCR5 | ALDH1A1 1533/4885USP2 4220/4885ALOX15 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.